What should I avoid while taking Tolazamide 500mg tablets?

Avoid excessive or chronic alcohol consumption. Ingesting alcohol may increase the risk of hypoglycemia. Take with food. Taking tolazamide with breakfast may help reduce the risk of hypoglycemia. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Tolazamide 500mg tablets?

Tolazamide 500mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Tolazamide 500mg tablets?

Tolazamide 500mg tablets is the generic name. It is available under brand names including: Tolazamide 500mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Tolazamide 500mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

500mg

Oral

Diabetes treatment (at risk)

A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

Active ingredients:

Tolazamide

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC A10BB05

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Diabetes treatment (at risk)

Check interactions for Tolazamide

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Tolazamide

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Tolazamide

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Tolazamide

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Tolazamide on the MHRA register

Tolazamide 500mg tablets

Imported (United States)

None

Imported

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Therapeutically similar medicines

Oral suspension

Same therapeutic group

Glibenclamide 6mg/ml oral suspension sugar free

Oral suspension

6mg

Same therapeutic group

Gliclazide 160mg tablets

Tablet

160mg

Same therapeutic group

Tolazamide 250mg tablets

Tablet

250mg

Same therapeutic group

Gliclazide 60mg modified-release tablets

Tablet

60mg

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42090511000001105

dm+d ID

42090511000001105

VTM (Virtual Therapeutic Moiety)

777796007

VMP (Virtual Medicinal Product)

42090511000001105

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

A10BB05

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 1 · Randomised trials: 1 · 1967–2023

Sort

Effects of Tolazamide and Exogenous Insulin on Pattern of Postprandial Carbohydrate Metabolism in Patients With Non-Insulin-Dependent Diabetes Mellitus: Results of Randomized Crossover Trial

R. Firth, P. Bell, M. Marsh, et al.

Diabetes, 1987

Randomised trial

Cited by 25

Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus.

R. Firth, P. Bell, R. Rizza

The New England journal of medicine, 1986

Cited by 136

Determining the Growth Mechanism of Tolazamide by Induction Time Measurement

Anuj Kuldipkumar, Glen S. Kwon, Geoff G. Z. Zhang

Crystal Growth & Design, 2006

Cited by 97

DFT investigation of the solid-state properties and Hirshfeld surface analysis of antidiabetic drugs: Acetohexamide and Tolazamide

R.L. Araújo, J.X. Lima Neto, U.L. Fulco, et al.

Chemical Physics Letters, 2023

Cited by 7

tolazamide, n.

Oxford English Dictionary, 2023

Effect of pressure on two polymorphs of tolazamide: why no interconversion?

A. Yu. Fedorov, D. A. Rychkov, E. A. Losev, et al.

CrystEngComm, 2017

Cited by 32

Tolazamide in the treatment of diabetes mellitus: clinical experience and review of the literature.

M. C. Balodimos, A. Marble

Current therapeutic research, clinical and experimental, 1971

Review

Cited by 1

Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography

Pingyang Tao, Zhao Li, Ashley G. Woolfork, et al.

Journal of Pharmaceutical and Biomedical Analysis, 2019

Cited by 22

Tolazamide
Serum Albumin
Hypoglycemic Agents

COMPARISON OF DIFFERENT COMPUTATIONAL APPROACHES FOR UNVEILING THE HIGH-PRESSURE BEHAVIOR OF ORGANIC CRYSTALS AT A MOLECULAR LEVEL. CASE STUDY OF TOLAZAMIDE POLYMORPHS

A. Yu. Fedorov, D. A. Rychkov

Journal of Structural Chemistry, 2020

Cited by 11

Impaired Granulocyte Adherence in Mildly Diabetic Patients: Effects of Tolazamide Treatment

J. Bagdade, E. Walters

Diabetes, 1980

Cited by 47

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

7 hours

Mechanism

Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pa…

Food interactions

2 warnings

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Rapidly and well absorbed from the gastrointestinal tract.

Half-life

7 hours

The average biological half-life of the drug is 7 hours.

Metabolism

0 to 70%

Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%.

Elimination

Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0% to 70%. They are excreted principally in the urine.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

Properties:

solid

Avg. mass: 311.40 Da

DrugBank indication

For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Also known as(30)

1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea

1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea

4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide

N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea

Tolazamid

Tolazamida

Tolazamide

Tolazamidum

Molecular properties(19)

Drug interactions(1509)

Known interactions with other medicines. Always consult a healthcare professional.

Pegvisomant

Moderate

DB00082

The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolazamide.

Check this interaction

Carbocisteine

Moderate

DB04339

The risk or severity of adverse effects can be increased when Tolazamide is combined with Carbocisteine.

Check this interaction

Chloramphenicol

Moderate

DB00446

The metabolism of Tolazamide can be decreased when combined with Chloramphenicol.

Check this interaction

Cimetidine

Moderate

DB00501

The serum concentration of Tolazamide can be increased when it is combined with Cimetidine.

Check this interaction

Fluconazole

Moderate

DB00196

The serum concentration of Tolazamide can be increased when it is combined with Fluconazole.

Check this interaction

Metreleptin

Moderate

DB09046

Metreleptin may increase the hypoglycemic activities of Tolazamide.

Check this interaction

Probenecid

Moderate

DB01032

The protein binding of Tolazamide can be decreased when combined with Probenecid.

Check this interaction

Ranitidine

Moderate

DB00863

The serum concentration of Tolazamide can be increased when it is combined with Ranitidine.

Check this interaction

Voriconazole

Moderate

DB00582

The serum concentration of Tolazamide can be increased when it is combined with Voriconazole.

Check this interaction

Clarithromycin

Moderate

DB01211

The serum concentration of Tolazamide can be increased when it is combined with Clarithromycin.

Check this interaction

Lipoic acid

Moderate

DB00166

The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Tolazamide.

Check this interaction

Rifampin

Moderate

DB01045

The serum concentration of Tolazamide can be decreased when it is combined with Rifampicin.

Check this interaction

Moxifloxacin

Moderate

DB00218

The therapeutic efficacy of Tolazamide can be increased when used in combination with Moxifloxacin.

Check this interaction

Grepafloxacin

Moderate

DB00365

The therapeutic efficacy of Tolazamide can be increased when used in combination with Grepafloxacin.

Check this interaction

Enoxacin

Moderate

DB00467

The therapeutic efficacy of Tolazamide can be increased when used in combination with Enoxacin.

Check this interaction

Pefloxacin

Moderate

DB00487

The therapeutic efficacy of Tolazamide can be increased when used in combination with Pefloxacin.

Check this interaction

Ciprofloxacin

Moderate

DB00537

The therapeutic efficacy of Tolazamide can be increased when used in combination with Ciprofloxacin.

Check this interaction

Trovafloxacin

Moderate

DB00685

The therapeutic efficacy of Tolazamide can be increased when used in combination with Trovafloxacin.

Check this interaction

Nalidixic acid

Moderate

DB00779

The therapeutic efficacy of Tolazamide can be increased when used in combination with Nalidixic acid.

Check this interaction

Rosoxacin

Moderate

DB00817

The therapeutic efficacy of Tolazamide can be increased when used in combination with Rosoxacin.

Check this interaction

Cinoxacin

Moderate

DB00827

The therapeutic efficacy of Tolazamide can be increased when used in combination with Cinoxacin.

Check this interaction

Lomefloxacin

Moderate

DB00978

The therapeutic efficacy of Tolazamide can be increased when used in combination with Lomefloxacin.

Check this interaction

Gatifloxacin

Moderate

DB01044

The therapeutic efficacy of Tolazamide can be increased when used in combination with Gatifloxacin.

Check this interaction

Norfloxacin

Moderate

DB01059

The therapeutic efficacy of Tolazamide can be increased when used in combination with Norfloxacin.

Check this interaction

Levofloxacin

Moderate

DB01137

The therapeutic efficacy of Tolazamide can be increased when used in combination with Levofloxacin.

Check this interaction

Gemifloxacin

Moderate

DB01155

The therapeutic efficacy of Tolazamide can be increased when used in combination with Gemifloxacin.

Check this interaction

Ofloxacin

Moderate

DB01165

The therapeutic efficacy of Tolazamide can be increased when used in combination with Ofloxacin.

Check this interaction

Sparfloxacin

Moderate

DB01208

The therapeutic efficacy of Tolazamide can be increased when used in combination with Sparfloxacin.

Check this interaction

Temafloxacin

Moderate

DB01405

The therapeutic efficacy of Tolazamide can be increased when used in combination with Temafloxacin.

Check this interaction

Fleroxacin

Moderate

DB04576

The therapeutic efficacy of Tolazamide can be increased when used in combination with Fleroxacin.

Check this interaction

Technetium Tc-99m ciprofloxacin

Moderate

DB05488

The therapeutic efficacy of Tolazamide can be increased when used in combination with Technetium Tc-99m ciprofloxacin.

Check this interaction

Garenoxacin

Moderate

DB06160

The therapeutic efficacy of Tolazamide can be increased when used in combination with Garenoxacin.

Check this interaction

Nemonoxacin

Moderate

DB06600

The therapeutic efficacy of Tolazamide can be increased when used in combination with Nemonoxacin.

Check this interaction

Flumequine

Moderate

DB08972

The therapeutic efficacy of Tolazamide can be increased when used in combination with Flumequine.

Check this interaction

Enrofloxacin

Moderate

DB11404

The therapeutic efficacy of Tolazamide can be increased when used in combination with Enrofloxacin.

Check this interaction

Orbifloxacin

Moderate

DB11443

The therapeutic efficacy of Tolazamide can be increased when used in combination with Orbifloxacin.

Check this interaction

Sarafloxacin

Moderate

DB11491

The therapeutic efficacy of Tolazamide can be increased when used in combination with Sarafloxacin.

Check this interaction

Difloxacin

Moderate

DB11511

The therapeutic efficacy of Tolazamide can be increased when used in combination with Difloxacin.

Check this interaction

Pazufloxacin

Moderate

DB11774

The therapeutic efficacy of Tolazamide can be increased when used in combination with Pazufloxacin.

Check this interaction

Prulifloxacin

Moderate

DB11892

The therapeutic efficacy of Tolazamide can be increased when used in combination with Prulifloxacin.

Check this interaction

Delafloxacin

Moderate

DB11943

The therapeutic efficacy of Tolazamide can be increased when used in combination with Delafloxacin.

Check this interaction

Sitafloxacin

Moderate

DB13261

The therapeutic efficacy of Tolazamide can be increased when used in combination with Sitafloxacin.

Check this interaction

Oxolinic acid

Moderate

DB13627

The therapeutic efficacy of Tolazamide can be increased when used in combination with Oxolinic acid.

Check this interaction

Rufloxacin

Moderate

DB13772

The therapeutic efficacy of Tolazamide can be increased when used in combination with Rufloxacin.

Check this interaction

Pipemidic acid

Moderate

DB13823

The therapeutic efficacy of Tolazamide can be increased when used in combination with Pipemidic acid.

Check this interaction

Methyclothiazide

Moderate

DB00232

The therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.

Check this interaction

Chlorthalidone

Moderate

DB00310

The therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorthalidone.

Check this interaction

Bendroflumethiazide

Moderate

DB00436

The therapeutic efficacy of Tolazamide can be decreased when used in combination with Bendroflumethiazide.

Check this interaction

Metolazone

Moderate

DB00524

The therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone.

Check this interaction

Benzthiazide

Moderate

DB00562

The therapeutic efficacy of Tolazamide can be decreased when used in combination with Benzthiazide.

Check this interaction

Showing 50 of 1509 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid excessive or chronic alcohol consumption. Ingesting alcohol may increase the risk of hypoglycemia.

Take With Food

Take with food. Taking tolazamide with breakfast may help reduce the risk of hypoglycemia.

Toxicity & overdose

Overdosage of sulfonylureas can produce hypoglycemia. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization.

How it works

Mechanism of action

Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.

Pharmacodynamics

Tolazamide is an oral blood glucose lowering drug of the sulfonylurea class. Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. Some patients who are initially responsive to oral hypoglycemic drugs, including tolazamide, may become unresponsive or poorly responsive over time. Alternatively, tolazamide may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose lowering actions, tolazamide produces a mild diuresis by enhancement of renal free water clearance.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Rapidly and well absorbed from the gastrointestinal tract.

Half-life

The average biological half-life of the drug is 7 hours.

Metabolism

Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%.

Route of elimination

Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0% to 70%. They are excreted principally in the urine.

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

ATP-sensitive inward rectifier potassium channel 11

BE0008670

KCNJ11

blocker

Specific functionankyrin binding

Cellular location

Membrane

General function & pharmacology

Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells .
PMID:29286281 PMID:34815345
Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.

Can be blocked by extracellular barium (By similarity). In pancreatic cells, it forms KATP channels with ABCC8/SUR1 .
PMID:29286281 PMID:34815345
Can form cardiac and smooth muscle-type KATP channels with ABCC9

ATP-sensitive inward rectifier potassium channel 10

BE0009591

KCNJ10

blocker

Specific functionATP binding

Cellular location

Membrane

General function & pharmacology

May be responsible for potassium buffering action of glial cells in the brain (By similarity). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it .
PMID:8995301
Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages .
PMID:8995301
The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium .
PMID:8995301
In the kidney, together with KCNJ16, mediates basolateral K(+) recycling in distal tubules; this process is critical for Na(+) reabsorption at the tubules PMID:24561201

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2C9Cytochrome P450 2C9

substrate

Scientific references(2)

Tal A.

Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus.

Diabetes & Metabolism Journal

202448(5):882-884. doi: 10.4093/dmj.2024.0479

PMID: 8237731 DOI: 10.4093/dmj.2024.0479

Granberry M.C., Fonseca V.A.

Cardiovascular Risk Factors Associated with Insulin Resistance.

American Journal of Cardiovascular Drugs

20055(3):201-209. doi: 10.2165/00129784-200505030-00006

PMID: 15901207 DOI: 10.2165/00129784-200505030-00006

ATC classification(2 codes)

ATC A10BB05

ATC G01AE10

Affected organisms(1)

Humans and other mammals

Experimental properties(4)

External resources(2)

RxList Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Tolazamide

DB00839

CAS number

1156-19-0

UNII (FDA)

9LT1BRO48Q

InChI Key (molecular fingerprint)

OUDSBRTVNLOZBN-UHFFFAOYSA-N

Additional database identifiers

ChEBI

9613

PubChem Compound

5503

PubChem Substance

46505642

KEGG Drug

D00379

ChemSpider

5302

BindingDB

50240099

PharmGKB

PA164774902

Therapeutic Targets Database

DAP000919

Wikipedia

Tolazamide

ChEMBL

CHEMBL817

ZINC

ZINC000000057512

RxCUI

10633

HUGO Gene Nomenclature Committee (HGNC)

HGNC:59

GenAtlas

ABCC8

GeneCards

ABCC8

GenBank Gene Database

L78243

GenBank Protein Database

1374919

Guide to Pharmacology

2594

UniProtKB

Q09428

UniProt Accession

ABCC8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6257

GenAtlas

KCNJ11

GeneCards

KCNJ11

GenBank Gene Database

D50582

GenBank Protein Database

1088445

IUPHAR

442

UniProtKB

Q14654

UniProt Accession

KCJ11_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6256

GeneCards

KCNJ10

Guide to Pharmacology

438

UniProtKB

P78508

UniProt Accession

KCJ10_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 8 Mar 2026

Back to medicines

Tolazamide 500mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
3

Chemical identifiers

Tolazamide

Additional database identifiers

DrugBank citations

Tolazamide 500mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science3

Chemical identifiers

Tolazamide

Additional database identifiers

DrugBank citations

Deep science
3